Translating IL-6 biology into effective treatments

EH Choy, F De Benedetti, T Takeuchi… - Nature Reviews …, 2020 - nature.com
Abstract In 1973, IL-6 was identified as a soluble factor that is secreted by T cells and is
important for antibody production by B cells. Since its discovery more than 40 years ago, the …

New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology

MD Giraldez, D Carneros, C Garbers… - Nature reviews …, 2021 - nature.com
IL-6 family cytokines are defined by the common use of the signal-transducing receptor
chain glycoprotein 130 (gp130). Increasing evidence indicates that these cytokines are …

Interleukin‐31: The “itchy” cytokine in inflammation and therapy

A Datsi, M Steinhoff, F Ahmad, M Alam, J Buddenkotte - Allergy, 2021 - Wiley Online Library
The cytokine interleukin‐31 has been implicated in the pathophysiology of multiple atopic
disorders such as atopic dermatitis (AD), allergic rhinitis, and airway hyper‐reactivity. In AD …

Targeting interleukin-6 in inflammatory autoimmune diseases and cancers

X Yao, J Huang, H Zhong, N Shen, R Faggioni… - Pharmacology & …, 2014 - Elsevier
Abstract Interleukin-6 (IL-6) is a pleiotropic cytokine with significant functions in the
regulation of the immune system. As a potent pro-inflammatory cytokine, IL-6 plays a pivotal …

Soluble gp130 is the natural inhibitor of soluble interleukin‐6 receptor transsignaling responses

T Jostock, J Müllberg, S Özbek, R Atreya… - European journal of …, 2001 - Wiley Online Library
Signal transduction in response to interleukin‐6 (IL‐6) requires binding of the cytokine to its
receptor (IL‐6R) and subsequent homodimerization of the signal transducer gp130. The …

Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation

J Berkes, VK Viswanathan, SD Savkovic, G Hecht - Gut, 2003 - gut.bmj.com
The effects of pathogenic organisms on host intestinal epithelial cells are vast. Innumerable
signalling pathways are triggered leading ultimately to drastic changes in physiological …

Characteristics of intestinal dendritic cells in inflammatory bowel diseases

AL Hart, HO Al-Hassi, RJ Rigby, SJ Bell, AV Emmanuel… - Gastroenterology, 2005 - Elsevier
Background & Aims: Dendritic cells (DCs) recognize and respond to microbial structures
using pattern recognition receptors, including Toll-like receptors (TLRs). In the intestine, DCs …

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

H Ito, M Takazoe, Y Fukuda, T Hibi, K Kusugami… - Gastroenterology, 2004 - Elsevier
Background & Aims: Interleukin-6 (IL-6) regulates immune response and inflammation. We
carried out a pilot placebo-controlled study to investigate the efficacy, pharmacokinetics, and …

Novel targeted therapies for inflammatory bowel disease

M Coskun, S Vermeire, OH Nielsen - Trends in pharmacological sciences, 2017 - cell.com
Our growing understanding of the immunopathogenesis of inflammatory bowel disease
(IBD) has opened new avenues for developing targeted therapies. These advances in …

Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer

R Atreya, MF Neurath - Clinical reviews in allergy & immunology, 2005 - Springer
Inflammatory bowel disease (IBD), which consists of Crohn's disease and ulcerative colitis,
is defined as a chronic inflammation of the gastrointestinbal tract. The etiopathogenetic …